NO20004583L - Crystalline form of paroxetine - Google Patents

Crystalline form of paroxetine

Info

Publication number
NO20004583L
NO20004583L NO20004583A NO20004583A NO20004583L NO 20004583 L NO20004583 L NO 20004583L NO 20004583 A NO20004583 A NO 20004583A NO 20004583 A NO20004583 A NO 20004583A NO 20004583 L NO20004583 L NO 20004583L
Authority
NO
Norway
Prior art keywords
paroxetine
crystalline form
free
crystalline
therapy
Prior art date
Application number
NO20004583A
Other languages
Norwegian (no)
Other versions
NO20004583D0 (en
Inventor
Andrew Simon Craig
Neal Ward
Wilson Mcilwaine
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805581.7A external-priority patent/GB9805581D0/en
Priority claimed from GBGB9813054.5A external-priority patent/GB9813054D0/en
Priority claimed from GBGB9817115.0A external-priority patent/GB9817115D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20004583D0 publication Critical patent/NO20004583D0/en
Publication of NO20004583L publication Critical patent/NO20004583L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ren, løsningsmiddel-fri, for eksempel krystallinsk, fri paroxetine-base; og dens anvendelse i terapi for å behandle depresjon.Pure, solvent-free, for example, crystalline, free paroxetine base; and its use in therapy to treat depression.

NO20004583A 1998-03-16 2000-09-14 Crystalline form of paroxetine NO20004583L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9805581.7A GB9805581D0 (en) 1998-03-16 1998-03-16 Novel compounds
GBGB9813054.5A GB9813054D0 (en) 1998-06-17 1998-06-17 Novel compounds
GBGB9817115.0A GB9817115D0 (en) 1998-08-06 1998-08-06 Novel compounds
PCT/GB1999/000793 WO1999047519A1 (en) 1998-03-16 1999-03-16 Crystalline form of paroxetine

Publications (2)

Publication Number Publication Date
NO20004583D0 NO20004583D0 (en) 2000-09-14
NO20004583L true NO20004583L (en) 2000-09-15

Family

ID=27269245

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004583A NO20004583L (en) 1998-03-16 2000-09-14 Crystalline form of paroxetine

Country Status (18)

Country Link
EP (1) EP1064282A1 (en)
JP (1) JP2002506865A (en)
KR (1) KR20010041947A (en)
CN (1) CN1300286A (en)
AP (1) AP2000001907A0 (en)
AU (1) AU2847199A (en)
BG (1) BG104839A (en)
BR (1) BR9908825A (en)
CA (1) CA2323896A1 (en)
EA (1) EA200000946A1 (en)
HU (1) HUP0101215A3 (en)
ID (1) ID27596A (en)
IL (1) IL138390A0 (en)
NO (1) NO20004583L (en)
PL (1) PL342931A1 (en)
SK (1) SK13622000A3 (en)
TR (1) TR200002675T2 (en)
WO (1) WO1999047519A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689805A8 (en) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
AR001982A1 (en) * 1995-02-06 1998-01-07 Smithkline Beecham Plc PAROXETINE CHLORHYDRATE ANHYDRATED, AND PROCEDURE FOR ITS PREPARATION

Also Published As

Publication number Publication date
BG104839A (en) 2001-09-28
PL342931A1 (en) 2001-07-16
TR200002675T2 (en) 2000-12-21
SK13622000A3 (en) 2001-03-12
EA200000946A1 (en) 2001-02-26
HUP0101215A3 (en) 2002-05-28
IL138390A0 (en) 2001-10-31
CA2323896A1 (en) 1999-09-23
KR20010041947A (en) 2001-05-25
BR9908825A (en) 2000-11-21
HUP0101215A2 (en) 2002-04-29
NO20004583D0 (en) 2000-09-14
CN1300286A (en) 2001-06-20
WO1999047519A1 (en) 1999-09-23
JP2002506865A (en) 2002-03-05
AP2000001907A0 (en) 2000-09-30
ID27596A (en) 2001-04-12
EP1064282A1 (en) 2001-01-03
AU2847199A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
TR200103216T2 (en) Pyrimidinone compositions
CY2473B1 (en) New phenanthridines.
NO983189L (en) New substituted imidazole compounds
BR0314603A (en) Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
BR9811956B1 (en) naphthyridinones and pharmaceutical composition comprising them.
AU8112101A (en) Non-imidazole aryloxypiperidines
NO952132L (en) Pharmacologically active pyridine derivatives and their preparation
BR0011130A (en) Metalloprotease inhibitors
TR200201144T2 (en) Substituted indoles for modulation of NFKB activity
AU8473301A (en) Non-imidazole aryloxyalkylamines
DK1363608T3 (en) Formulations comprising ibuprofen and diphenhydramine and their use in the treatment of sleep disorders
DE69914357D1 (en) PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINE
ATE400258T1 (en) TRANSDERMAL BUPRENORPHINE DOSING SCHEME FOR PAIN RELIEF
SE9802208D0 (en) Novel compounds
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE69525740D1 (en) Special compositions containing halofantrine
TR199903141T2 (en) CD154 blockade therapy for therapeutic protein blocker syndrome.
TR200101693T2 (en) Treatment of follicular lymphomas using inhibitors of the lysophoxin (LT) expression pathway.
NO20020031L (en) Dihydrobenzodiazepines and their use in the treatment of dyslipidemia
TR200403001T3 (en) A process for the treatment of lovastatin and simvastatin with reduced dimeric impurity levels
NO20004583L (en) Crystalline form of paroxetine
SE9802209D0 (en) Novel compounds
NZ515531A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
AP2000002017A0 (en) Salts of paroxetine.
UY26648A1 (en) VASOPEPTIDASE INHIBITORS TO TREAT ISOLATED SYSTOLIC HYPERTENSION

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application